Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PHGDH | O43175 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GSDMD | P57764 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18017276 | 0.85 | ALDH1A1 (0.73) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| SCHEMBL28574961 | 0.84 | TSHR (0.54) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| S-Methyl Diethylcarbamothioate SCHEMBL1051392 | 0.79 | — | — | |
| SCHEMBL11393115 | 0.77 | — | — | |
| SCHEMBL27621822 | 0.77 | — | — | |
| SCHEMBL24470878 | 0.77 | TSHR (0.46) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| SCHEMBL21221413 | 0.77 | PHGDH (0.50) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| SCHEMBL134304 | 0.77 | TSHR (0.65) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| SCHEMBL4263485 | 0.75 | TSHR (0.62) | ALDH1A1ALDH2LMNAKMT2AMGLL | |
| SCHEMBL9420118 | 0.73 | ALDH1A1 (0.49) | ALDH1A1ALDH2LMNAKMT2AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632420-B1 | TREATMENT OF FIBROSIS | UNIV BIRMINGHAM (GB) | 2023-09-27 | — | — | EP | claimed |
| US-9937133-B2 | Treatment of fibrosis | UCL BUSINESS PLC (GB) | 2018-04-10 | — | — | US | claimed |
| EP-3137068-A1 | TREATMENT OF FIBROSIS | UCL Business Plc. (GB) | 2017-03-08 | — | — | EP | claimed |
| US-20170042838-A1 | Treatment of Fibrosis | THE UNIVERSITY OF BIRMINGHAM (GB) | 2017-02-16 | — | — | US | claimed |
| WO-2015166277-A1 | TREATMENT OF FIBROSIS | UCL BUSINESS PLC (GB) | 2015-11-05 | — | — | WO | claimed |
| WO-2008045017-A2 | SARS AND EBOLA INHIBITORS AND USE THEREOF, AND METHODS FOR THEIR DISCOVERY | DIAMOND SCOTT L (US) | 2008-04-17 | — | — | WO | claimed |
| US-20070203073-A1 | SARS and Ebola inhibitors and use thereof, and methods for their discovery | DIAMOND SCOTT L | 2007-08-30 | — | — | US | claimed |
| US-4412072-A | STABILIZED WITH A PEROXIDE, SULFUR, POLYSULFIDE, METAL SULFIDE OR A HALOGEN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-25 | — | — | US | claimed |
| EP-3632420-B1 | TREATMENT OF FIBROSIS | UNIV BIRMINGHAM (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20220347125-A1 | ANTITUMOR AGENT AND COMPOUNDING AGENT | KEIO UNIVERSITY (JP) | 2022-11-03 | — | — | US | disclosed |
| EP-3973991-A1 | ANTI-TUMOR AGENT AND COMPOUNDING AGENT | Keio University (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| WO-2020230701-A1 | ANTITUMOR AGENT AND COMPOUNDING AGENT | 学校法人 慶應義塾 | 2020-11-19 | — | — | WO | disclosed |
| EP-3632420-A1 | TREATMENT OF FIBROSIS | The University Of Birmingham (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-1999034784-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DISULFIRAM FOR INHIBITING ANGIOGENESIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1999-07-15 | — | — | WO | disclosed |
| US-5290834-A | Method for controlling elution rate of agent | ROHM & HAAS COMPANY (US) | 1994-03-01 | — | — | US | disclosed |
| EP-0042701-B2 | ISOCYANATE COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | disclosed |
| EP-0042701-B1 | ISOCYANATE COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| US-4412072-A | STABILIZED WITH A PEROXIDE, SULFUR, POLYSULFIDE, METAL SULFIDE OR A HALOGEN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-25 | — | — | US | disclosed |
| EP-0042701-A2 | Isocyanate composition | Takeda Chemical Industries, Ltd. (JP) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | ALDH1A1 4306/4885ALDH2 4145/4885LMNA 1046/4885 |
| US-20220347125-A1 | ANTITUMOR AGENT AND COMPOUNDING AGENT | GSTA1, GSTP1, GSTA2 | ALDH1A1 692/4885ALDH2 195/4885LMNA 4828/4885 |
| US-20070203073-A1 | SARS and Ebola inhibitors and use thereof, and methods for their discovery | CTSL, CTSV, CTSZ | ALDH1A1 2172/4885ALDH2 1855/4885LMNA 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.